Changes in HIV and AID in the United States: Entering the third decade

Current HIV/AIDS Reports

Volumn 1, Issue 4, 2004, Pages 153-158

  Kellerman, Scott ^a   Begley, Elin ^b   Boyett, Brian ^b   Clark, Hollie ^b   Schulden, Jeff ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NONE

Author keywords

Human Immunodeficiency Virus; Human Immunodeficiency Virus Diagnosis; Human Immunodeficiency Virus Infection; Human Immunodeficiency Virus Prevention; Human Immunodeficiency Virus Testing

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE TRANSMISSION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; INFANT; MALE; REVIEW; STATISTICS; SUBSTANCE ABUSE; UNITED STATES;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DISEASE TRANSMISSION, VERTICAL; FEMALE; HOMOSEXUALITY, MALE; HUMANS; INFANT; MALE; SUBSTANCE ABUSE, INTRAVENOUS; UNITED STATES;

EID: 24144496909     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-004-0024-9     Document Type: Article

References (74)

1. AIDS Epidemic Update. December 2003. UNAIDS. Accessible at http://www.unaids.org/html/pub/publications/irc-pub06/ jc943-epiupdate2003_en_pdf.htm. Accessed June 14, 2004.
2. Centers for Disease Control and Prevention: HIV/AIDS surveillance report 2002, 14:1–48.
3. Karon JM, Fleming PL, Steketee RW, DeCock KM: HIV in the United States at the turn of the century: an epidemic in transition. Am J Public Health 2001, 91:1060–1068.
4. Fleming PL, Byers RH, Sweeney PA, et al.: HIV Prevalence in the United States, 2000. In Presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24–28, 2002. Abstract 11.
5. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring of human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Morb Mort Wkly Rep 1999, 48:1–31. This CDC report provides the rationale for recommending combined HIV/AIDS surveillance, and offers guidance to state and local health departments that have recently expanded or soon expect to expand their AIDS surveillance systems to include reporting of HIV cases. The report also includes a revised case definition of HIV infection in adults and children, effective January 2000.
6. Hader SL, Smith DK, Moore JS, Holmberg, SD: HIV infection in women in the United States: status at the millennium. JAMA 2001, 285:1186–1192.
7. Rosenberg P, Biggar R: Trends in HIV incidence among young adults in the United States. JAMA 1998, 279:1894–1899. This paper describes trends in HIV incidence in young persons (based on back-calculation from AIDS cases), between 1988 and 1993. During that time, HIV prevalence in white men decreased by 50%, while staying relatively stable in black and Hispanic men. Conversely, HIV prevalence rose in women primarily because of heterosexual transmission.
8. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Supplemental Report: Cases of HIV Infection and AIDS in the United States, by Race/Ethnicity. MMWR Morb Mort Wkly Rep 1998-2002, 10:1–38.
9. Adimora AA, Schoenbach VJ: Contextual factors and the black-white disparity in heterosexual HIV transmission. Epidemiology 2002, 13:707–712.
10. Laumann EO, Youm Y: Racial/ethnic group differences in the prevalence of sexually transmitted diseases in the United States: a network explanation. Sex Transm Dis 1999, 26:250–261.
11. Smith DK, Gwinn M, Selik RM, et al.: HIV/AIDS among African Americans: Progress or progression? AIDS 2000, 14:1237–1248.
12. Morales LS, Cunningham WE, Galvan FH, et al.: Sociodemographic differences in access to care among Hispanic patients who are HIV infected in the United States. Am J of Public Health 2004, 94:1118–1121.
13. Catania JA, Osmond D, Stall RD, et al.: The continuing HIV epidemic among men who have sex with men. Am J Public Health 2001, 91:907–914.
14. Harawa NT, Greenland S, Bingham TA, et al.: Associations of race/ethnicity with HIV prevalence and HIV-related behaviors among young men who have sex with men in 7 urban centers in the United States. J Acquir Immune Defic Syndr 2004, 35:526–536.
15. Fleming P, Ward J, Karon J, et al.: Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS 1998, 12(Suppl A):S55-S61. This paper documents trends in decreasing AIDS incidence and deaths from AIDS, from 1987 through 1996, in the United States. In light of theses declines, the authors describe a reassessment of the structure and goals of public health surveillance and of prevention and care programs.
16. Palella F Jr, Delaney K, Moorman A, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853–860. This paper was one of the first to show that the recent declines in morbidity and mortality due to AIDS are attributable to the use of more intensive antiretroviral therapies.
17. Savin CA: The changing clinical epidemiology of AIDS in the highly active antiretroviral therapy era. AIDS 2002, 16(suppl 4):S61-S68.
18. Fischl M, Richman D, Grieco M, et al.: The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS andAIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987, 317:185–191.
19. Kitchen V, Skinner C, Ariyoshi K, et al.: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952–955.
20. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1 protease inhibitor associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1998, 351:1881–1883.
21. Tebas P, Powderly WG, Claxton S, et al.: Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000, 14:F63-F67.
22. Sulkowski M, Thomas D, Chaisson R, Moore R: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283:74–80.
23. Selik RM, Byers RH, Dworkin MS: Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987–1999. J Acquir Immune Defic Syndr 2002, 29:378–387.
24. Chiao EY, Krown SE: Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr Opin Oncol 2003, 15:389–397.
25. Selik RM, Rabkin CS: Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst 1998, 90:1300–1302.
26. Sullivan P, Chu S, Fleming P, Ward J: Changes in AIDS incidence for men who have sex with men, United States 1990–1995. AIDS 1997, 11:1641–1646.
27. Denning PH, Jones JL, Ward J: Recent trends in the HIV epidemic in adolescent and young adult gay and bisexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1997, 16:374–379.
28. Katz M, McFarland W, Guillin V, et al.: Continuing high prevalence of HIV and risk behaviors among young men who have sex with men: the young men’s survey in the San Francisco Bay Area in 1992 to 1993 and in 1994 to 1995. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 19:178–181.
29. Centers for Disease Control and Prevention: HIV/AIDS among men of color who have sex with men-United States, January 1989–December 1998. MMWR Morb Mort Wkly Rep 2000, 49:4–11.
30. Ekstrand M, Stall R, Paul J, et al.: Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. AIDS 1999, 13:1525–1533. This paper is one of the first to document a return to high-risk behaviors in some high-risk groups. The authors postulate that current AIDS prevention efforts may not be offering effective prevention messages to new generations of gay or bisexual men or to those categorized as high-risk for transmission.
31. Suarez TP, Kelly JA, Pinkerton SD, et al.: Influence of a partner’s HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr 2001, 28:471–477.
32. Stockman JD, Schwarcz SK, Butler LM, et al.: HIV prevention fatigue among high-risk populations in San Francisco. J Acquir Immune Defic Syndr 2004, 35:432–434.
33. McFarland W, Kellogg TA, Dilley J, Katz MH: Estimation of human immunodeficiency virus (HIV) seroincidence among repeat anonymous testers in San Francisco. Am J Epidemiol 1997, 146:662–664.
34. Kellogg T, McFarland W, Katz M: Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco [letter]. AIDS 1999, 13:2303–2304.
35. Wolitski, RJ, Valdiserri RO, Denning PH, Levine WC: Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J Public Health 2001, 91:883–888.
36. Centers for Disease Control and Prevention: Resurgent bacterial sexually transmitted disease among men who have sex with men, King County, Washington, 1997–1999. MMWR Morb Mort Wkly Rep. 1999, 48:773–777.
37. Centers for Disease Control and Prevention: Increases in unsafe sex and rectal gonorrhea among men who have sex with men, San Francisco, California, 1994–1997. MMWR Morb Mort Wkly Rep. 1999, 48:45–48.
38. Do AN, Hanson DL, Dworkin MS, et al.: Risk factors for and trends in gonorrhea incidence among persons infected with HIV in the United States. AIDS 2001, 15:1149–1155.
39. Centers for Disease Control and Prevention: HIV prevention through early detection and treatment of sexually transmitted diseases-United States. MMWR Morb Mort Wkly Rep 1998, 47(RR-12):1–31.
40. Adams AL, Becker TM, Lapidus JA, et al.: HIV infection risk, behaviors, and attitudes about testing: are perceptions changing? Sex Transm Dis 2003, 30:764–768.
41. Des Jarlais D, Friedman SR: Fifteen years of research on preventing HIV infection among injecting drug users: what we have learned, what we have not learned, what we have done, what we have not done. Public Health Rep 1998, 113(Suppl 1):182–188.
42. Des Jarlais D, Hagan H, Friedman SR: Maintaining low HIV seroprevalence in populations of injecting drug users. JAMA 1995, 274:1226–1231.
43. Des Jarlais D, Friedman SR, Perlis T, et al.: Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:67–72.
44. Centers for Disease Control and Prevention (CDC): National HIV prevalence surveys, 1997 summary. Atlanta: division of HIV/AIDS prevention-surveillance and epidemiology, national center for HIV, STD, and TB prevention, CDC; 1998:1–25.
45. Des Jarlais DC, Marmor M, Friedmann P, et al.: HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic. Am J Public Health 2000, 90:352–359. This compendium of 10 studies documents a large decrease in HIV incidence among New York City injection drug users (weighted average: less than 1 per 100 person-years). The authors note that, while HIV infections continue to occur in this cohort, they do so at much lower levels than previously observed. It is not possible to determine the cause(s) of this new incidence, but low incidence among IDUs in the United States appears to be a pattern in existing cohort studies.
46. Centers for Disease Control and Prevention: HIV diagnoses among injection-drug users in the states with HIV surveillance -25 states, 1994–2000. MMWR Morb Mort Wkly Rep. 2003, 52:634–636.
47. Community Epidemiology Work Group (CEWG), National Institutes of Health, National Institute on Drug Abuse: Drug abuse highlights for the United States. Presented at the meeting of the CEWG. Miami, FL, 1998; Epidemiologic Trends in Drug Abuse Advance Report, December, 1998, Accessible at http://www.cdmgroup.com/cewg/pubs.htm. Accessed June 15, 2004.
48. Klevens R, Fleming P, Neal J, Li J: Is there really a heterosexual AIDS epidemic in the United States? Findings from a multisite validation study, 1992–1995. Mode of Transmission Validation Study Group. Am J Epidemiol 1999, 149:75–84.
49. Chakrabory H, Sen PK, Helms RW, et al.: Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: A probabilistic empiric model. AIDS 2001, 15:621–627.
50. DeCock KM, Weiss HA: The global epidemiology of HIV/ AIDS. Trop Med IntHealth 2000, 5:A3-A9.
51. Quinn TC, Wawer MJ, Sewankambo N, et al.: Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000, 342:921–929.
52. Royce R, Sena M, Cates W, Cohen M: Sexual transmission of HIV. N Engl J Med 1997, 336:1072–1078. [Published erratum appears in N Engl J Med 1997, 337:799.
53. Padian N, Shiboski S, Glass S, Vittinghoff E. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: results of a ten-year study. Am J Epidemiol 1997, 146:350–357.
54. Ehrhardt AA, Exner TM: Prevention of sexual risk behavior for HIV infection with women. AIDS 2000, 14(Suppl 2):S53-S58.
55. Garcia-Moreno C, Watts C: Violence against women: its importance for HIV/AIDS. AIDS 2000, 14(Suppl 2):S53-S65.
56. Cooper ER, Charurat M, Mofensen L, et al.: Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr, 2002, 29:484–494.
57. Mofensen LW: Successes and challenges in the perinatal HIV-1 epidemic in the United States as illustrated by the HIV-1 serosurvey of childbearing women. Arch Pediatr Adolesc Med 2004, 158:422–425.
58. Dorenbaum A, Cunningham CK, Gelber RD, et al.: Two-dose intrapartum/newborn nervirapine and standard antiretroviral therapy to reduce perinatal HIV-1 transmission: a randomized trial. JAMA 2002, 288:189–198.
59. Bulterys M, Jamieson DJ, O’Sullivan MJ, et al.: Rapid HIV-1 testing during labor: a multicenter study. JAMA 2004, 292:219–223.
60. Cunningham C, Balasubramanian R, Delke I, et al.: The impact of race/ethnicity on mother-to-child HIV transmission in the United States in Pediatric AIDS clinical trials group protocol 316. J Acquire Immune Defic Syndr 2004, 36:800–807.
61. Do AN, Ciesielski CA, Metler RP, et al.: Occupationally acquired human immunodeficiency virus (HIV) infection: national case surveillance data during 20 years of the HIV epidemic in the United States. Infect Control Hosp Epidemiol 2003, 24:86–96.
62. Alvarado-Ramy F, Beltrami EM: New guidelines for occupational exposure to blood-borne viruses. Cleve Clin J Med 2003, 70(5):457–465.
63. Goodnough LT, Shander A, Brecher ME: Transfusion medicine: looking to the future. Lancet 2003, 361:161–169.
64. Busch MP, Kleinman SH, Jackson B, et al.: Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: report of the Interorganizational Task Force on Nucleic Acid Amplification. Transfusion 2000, 40:143–159.
65. Pretty IA, Anderson GS, Sweet DJ: Human bites and the risk of human immunodeficiency virus transmission. Am J Forensic Med Pathol 1999, 20:232–239.
66. Mast EE, Goodman RA, Bond WW, et al.: Transmission of bloodborne pathogens during sports: risk and prevention. Ann Intern Med 1995, 122:28–35.
67. Lindegren M, Hanson I, Hammett T, et al.: Sexual abuse of children: intersection with the HIV epidemic. Pediatrics 1998, 102:E46.
68. Kellerman SE, Do A, Metler R, Hammett T, Sullivan P: Intentional self-inoculation with HIV-positive blood: a case series from the Centers for Disease Control and Prevention HIV/ AIDS Surveillance System. AIDS. 2004, 18:965–968.
69. Chang ML, Vitek C, Esparza J, WHO-UNAIDS Vaccine Initiative: public health considerations for the use of a first generation HIV vaccine. Report from a WHO-UNAIDS-CDC consultation, Geneva, 20–21 November 2002. AIDS 2003, 17:W1-W10.
70. Calarota SA, Weiner DB: Present status of human HIV vaccine development. AIDS 2003, 17(Suppl 4):S73-S84.
71. Vastag B: HIV vaccine efforts inch forward. JAMA 2001, 286:1826–1828.
72. Frey S: HIV vaccines. Infect Dis Clin North Am 1999, 13:95–112.
73. Janssen RS, Satten GA, Stramer SL, et al.: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280:42–48. [Published erratum: JAMA 1999, 281:1893.]
74. Centers for Disease Control and Prevention. Advancing HIV prevention: new strategies for a changing epidemic -United States. MMWR Morb Mort Wkly Rep 2003, 452:329–332.